How patients with multiple sclerosis weigh treatment risks and benefits.

• DOI: 10.1037/hea0000626
• Publication Date: 2018-06-04T14:15:17Z
• Authors: Jared M. Bruce; David P. Jarmolowicz; Sharon Lynch; Joanie Thelen; Seung-Lark Lim; Julia Smith; Delwyn Catley; Amanda S. Bruce
• Keywords: PsycINFO

Although the effectiveness and risks of multiple sclerosis (MS) therapies are established, relatively little is known about how these benefits perceived weighed by patients. This risk-benefit trade-off important for clinicians, industry, regulators to consider when determining which develop, approve clinical use, recommend individual The primary objective present study was describe differences in MS patients weigh making treatment decisions.Two hundred ninety with completed tasks assessing their willingness take a hypothetical disease-modifying therapy (DMT) at varying levels efficacy, side effect probability, severity. Patients also questionnaires knowledge, medication beliefs, health care climate, disease severity.Patients progressive course reported increased DMT compared relapsing-remitting secondary courses. were less willing initiate across range efficacies effects if they had never taken DMT, more complementary alternative or history discontinuing DMTs due effects. More knowledge associated DMT.The results represent an initial step understanding chronic balance initiation. Extension this research may have implications pharmaceutical development, physician-patient interaction, adherence intervention, education. (PsycINFO Database Record